Sirnaomics Ltd (2257.HK) Q4 2025 Earnings Report

Sirnaomics Ltd delivered a materially loss-making QQ4 2025 quarter with modest revenue generation and a heavy R&D/SG&A burn characteristic of early-stage RNA therapeutics developers. Reported in USD, the quarter ended 2025-12-31 shows revenue of $0.89 million against cost of revenue of $0.89 million, producing a gross loss of $0.89 million. R&D expense rose to $6.67 million, SG&A/other operating costs remained elevated, and total operating expenses reached $9.77 million, resulting in an EBITDA of $(8.88) million and a net income of $(10.73) million, or $(0.11) per share on a diluted basis, for 4Q25. Management commentary (when available in earnings materials) typically centers on advancing a pipeline of STP-series candidates and strategic partnering for late-stage development; however, explicit guidance for 2026 remains unreported in the provided dataset. Net cash position stands at approximately $13.5 million in cash and cash equivalents with total debt around $9.3 million, yielding a net debt position of about $(4.2) million. Notably, the company carries a negative shareholders’ equity of about $(9.9) million, reflecting ongoing accumulated losses and a capital-light, pre-commercial milestone profile. In sum, the quarter underscores fundamental revenue underperformance relative to R&D-led burn, a fragile liquidity cushion, and a need for external financing or transformative partnerships to extend runway and de-risk the pipeline.